Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Thymus Neoplasms 1Thymoma 1Neoplasm Metastasis 1Hyperplasia 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 3Quality of Life 2Proton Therapy 2Immunotherapy 2Drug Therapy 2fludarabine 1epacadostat 1bosutinib 1amrubicin 1alovudine 1Tumor Burden 1Sunitinib 1Radiotherapy 1Radiosurgery 1Radiation 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Histocompatibility Testing 1Erlotinib Hydrochloride 1Cyclophosphamide 1Blood Specimen Collection 1Biological Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymus Neoplasms × alovudine × Thoracic × Clear all
NCT01610544 2018-07-05

18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperplasia, Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡